261 related articles for article (PubMed ID: 30171655)
1. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
[TBL] [Abstract][Full Text] [Related]
2. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Zörner B; Kapitza S; Reuter K; Lörincz L; Weller D; Sutter T; Killeen T; Gruber P; Petersen JA; Weller M; Linnebank M
Neurology; 2017 Feb; 88(9):832-841. PubMed ID: 28148629
[TBL] [Abstract][Full Text] [Related]
3. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
[TBL] [Abstract][Full Text] [Related]
4. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.
Weller D; Lörincz L; Sutter T; Reuter K; Linnebank M; Weller M; Zörner B; Filli L
J Neurol Sci; 2020 Sep; 416():116978. PubMed ID: 32559515
[TBL] [Abstract][Full Text] [Related]
5. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Hupperts R; Lycke J; Short C; Gasperini C; McNeill M; Medori R; Tofil-Kaluza A; Hovenden M; Mehta LR; Elkins J
Mult Scler; 2016 Feb; 22(2):212-21. PubMed ID: 25921050
[TBL] [Abstract][Full Text] [Related]
6. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
Savin Z; Lejbkowicz I; Glass-Marmor L; Lavi I; Rosenblum S; Miller A
J Neurol Sci; 2016 Jan; 360():102-9. PubMed ID: 26723984
[TBL] [Abstract][Full Text] [Related]
7. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
[TBL] [Abstract][Full Text] [Related]
8. Effects of prolonged-release fampridine on multiple sclerosis-related gait impairments. A crossover, double-blinded, placebo-controlled study.
Valet M; El Sankari S; Van Pesch V; Detrembleur C; Lejeune T; Stoquart G
Clin Biomech (Bristol, Avon); 2021 Jun; 86():105382. PubMed ID: 34000628
[TBL] [Abstract][Full Text] [Related]
9. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T
Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976
[TBL] [Abstract][Full Text] [Related]
10. A guide to treating gait impairment with prolonged-release fampridine (Fampyra
Ramió-Torrentà L; Álvarez-Cermeño JC; Arroyo R; Casanova-Estruch B; Fernández O; García-Merino JA; Hernández MA; Izquierdo G; Martínez-Yélamos S; Meca J; Moral E; Olascoaga J; Prieto JM; Saiz A
Neurologia (Engl Ed); 2018 Jun; 33(5):327-337. PubMed ID: 26873645
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
Hobart J; Ziemssen T; Feys P; Linnebank M; Goodman AD; Farrell R; Hupperts R; Blight AR; Englishby V; McNeill M; Chang I; Lima G; Elkins J;
CNS Drugs; 2019 Jan; 33(1):61-79. PubMed ID: 30535670
[TBL] [Abstract][Full Text] [Related]
12. Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life.
Allart E; Benoit A; Blanchard-Dauphin A; Tiffreau V; Thevenon A; Zephir H; Outteryck O; Lacour A; Vermersch P
J Neurol; 2015 Aug; 262(8):1936-45. PubMed ID: 26041616
[TBL] [Abstract][Full Text] [Related]
13. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
Broicher SD; Filli L; Geisseler O; Germann N; Zörner B; Brugger P; Linnebank M
J Neurol; 2018 May; 265(5):1016-1025. PubMed ID: 29464379
[TBL] [Abstract][Full Text] [Related]
14. Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine.
Macdonell R; Nagels G; Laplaud DA; Pozzilli C; de Jong B; Martins da Silva A; Nicholas R; Lechner-Scott J; Gaebler JA; Agarwal S; Wang P; Yeh M; Hovenden M; Soelberg Sørensen P
Mult Scler; 2016 Jun; 22(7):944-54. PubMed ID: 26447066
[TBL] [Abstract][Full Text] [Related]
15. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
Stellmann JP; Jlussi M; Neuhaus A; Lederer C; Daumer M; Heesen C
J Neurol Sci; 2016 Sep; 368():318-25. PubMed ID: 27538657
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
17. Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
Ghorbanpour S; Rahimibarghani S; Rohani S; Rastkar M; Ghajarzadeh M
Neurol Sci; 2023 Sep; 44(9):3059-3069. PubMed ID: 37055710
[TBL] [Abstract][Full Text] [Related]
18. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
[TBL] [Abstract][Full Text] [Related]
19. Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.
Kim ES
Drugs; 2017 Sep; 77(14):1593-1602. PubMed ID: 28864863
[TBL] [Abstract][Full Text] [Related]
20. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
van Munster CEP; Kaya L; Lam KH; Kalkers NF; Killestein J; Uitdehaag BMJ
Mult Scler Relat Disord; 2020 Feb; 38():101489. PubMed ID: 31731213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
